Effects of sulfotanshinone sodium injection on the pharmacokinetics and pharmacodynamics of warfarin in rats in vivo

References

• Altman R, Vidal HO. (2011). Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real word) perspective. Thromb J 9:12.
   PubMedGoogle Scholar
• Burn J, Pirmohamed M. (2018). Direct oral anticoagulants versus warfarin: is new always better than the old? Open Heart 5:e000712.
   PubMed Web of Science ®Google Scholar
• Chen D, Lin XX, Huang WH, et al. (2016). Sodium tanshinone IIA sulfonate and its interactions with human CYP450s. Xenobiotica 46:1085–8.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tu JH, He Y, et al. (2009). Effect of sodium tanshinone IIA sulfonate on the activity of CYP1A2 in healthy volunteers. Xenobiotica 39:508–13.
   PubMed Web of Science ®Google Scholar
• Ding TG, Zhang YJ, Chen A, et al. (2015). Effects of Cucurbitacin E, a tetracyclic triterpene compound from Cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats. Basic Clin Pharmacol Toxicol 116:385–9.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Adcock DM. (2008). Standardization of the INR: how good is your laboratory's INR and can it be improved? Semin Thromb Hemos 34:593–603.
   PubMed Web of Science ®Google Scholar
• Ge B, Zhang Z, Zuo Z. (2016). Radix Puerariae lobatae (Gegen) suppresses the anticoagulation effect of warfarin: a pharmacokinetic and pharmacodynamics study. Chin Med 11:7.
   PubMed Web of Science ®Google Scholar
• Guideline on the Investigation of Bioequivalence. (2010). London: European Medicines Agency (EMA). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
   Google Scholar
• Hen F, Zhong GP, Zhao LZ, et al. (2009). Inductive effects of tanshinone IIA on the activity of cytochrome P450 enzyme in rats. Chin Tradit Herb Drugs 40:938–42.
   Google Scholar
• Huang XH, Chen ZY, Zheng QS, et al. (2004). Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Clin Pharmacol Ther 9:1069–72.
   Google Scholar
• Jackevicius CA, Ton MN. (2009). Enhanced interaction between warfarin and high-dose ketoconazole: a case report. J Med Case Rep 2009:1–3.
   Google Scholar
• Jin S, Zhang YF, Chen XY, et al. (2012). Enantioselective determination of R-warfarin/S-warfarin in human plasma using liquid chromatography–tandem mass spectrometry and its application in a drug–drug interaction study. Acta Pharm Sin 47:105–9.
   Google Scholar
• Johnson JA, Gong L, Whirl-Carrillo M, et al. (2011). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90:625–9.
   PubMed Web of Science ®Google Scholar
• Jonas DE, McLeod HL. (2009). Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30:375–86.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang Y, Xing C, et al. (2015). Tanshinone IIA represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-kB/JNK signaling. Int Immunopharmacol 28:382–9.
   PubMed Web of Science ®Google Scholar
• Liu F, Yu G, Wang G, et al. (2012). An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. PLoS One 7:e42138.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu S, Shi Y, et al. (2018). Effects of safflower injection on the pharmacodynamics and pharmacokinetics of warfarin in rats. Xenobiotica 48:818–23.
   PubMed Web of Science ®Google Scholar
• Maione F, Cantone V, Chini MG, et al. (2015). Molecular mechanism of tanshinone IIA and cryptotanshinone in platelet anti-aggregating effects: an integrated study of pharmacology and computational analysis. Fitoterapia 100:174–8.
   PubMed Web of Science ®Google Scholar
• Maione F, De Feo V, Caiazzo E, et al. (2014). Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway. J Ethnopharmacol 155:1236–42.
   PubMed Web of Science ®Google Scholar
• Marengoni A, Pasina L, Concoreggi C, et al. (2014). Understanding adverse drug reactions in older adults through drug–drug interactions. Eur J Intern Med 25:843–6.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T. (2015). Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 386:281–91.
   PubMed Web of Science ®Google Scholar
• Mei YF, Zhang DS. (2014). Pharmacological actions and therapeutic applications of tanshinone IIA. Actan Europharmacol 4:55–64.
   Google Scholar
• Mustafa O, Afsin I, Kusku KS. (2019). Bleeding complications in warfarin-treated patients admitted to the emergency department. J Clin Med Res 11:106–13.
   PubMedGoogle Scholar
• Na KX. (2018). Which is better, new oral anticoagulants or warfarin? Capital Food Med 25:6.
   Google Scholar
• Obreli-Neto PR, Nobili A, De Oliveira Baldoni A, et al. (2012). Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol 68:1667–76.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhang R, Sun J, et al. (2008). Inhibitory effects of seven components of Danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36:1308–14.
   PubMed Web of Science ®Google Scholar
• Qiu X, Miles A, Jiang X, et al. (2012). Sulfotanshinone sodium injection for unstable angina pectoris: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2012:715790.
   PubMed Web of Science ®Google Scholar
• Saczynski JS, Spencer FA, Gore JM, et al. (2008). Twenty-year trends in the incidence of stroke complicating acute myocardial infarction: Worcester Heart Attack Study. Arch Intern Med 168:2104–10.
   PubMedGoogle Scholar
• Silva D, Sobel MS. (2002). Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg 15:256–7.
   PubMedGoogle Scholar
• Sun J, Lu Y, Li YT, et al. (2017). Influence of Shenxiong glucose injection on the activities of six CYP isozymes and metabolism of warfarin in rats assessed using probe cocktail and pharmacokinetic approaches. Molecules 22:1994.
   PubMed Web of Science ®Google Scholar
• Takeda K, Ikenaka Y, Tanikawa T, et al. (2016). Novel revelation of warfarin resistant mechanism in roof rats (Rattus rattus) using pharmacokinetic/pharmacodynamic analysis. Pestic Biochem Physiol 134:1–7.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Le Heuzey JY, Mabo P. (2015). Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 71:549–67.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Kuo YH, Peng HC, et al. (2003). Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome p4501A2. Xenobiotica 33:603–13.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Kuo YH, Wang SY, et al. (2004). Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci 74:885–96.
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, et al. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–92.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhou S, Xu L, et al. (2013). Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: blockade by tanshinone IIA. J Ethnopharmacol 145:152–61.
   PubMed Web of Science ®Google Scholar
• Wang QR, Ynag ZQ, Cai LL. (2017). Effect of sulfotanshinone sodium injection on cardiac pump function and prognosis in patients with acute myocardial infarction complicated by cardiogenic shock. J Crit Care Intern Med 23:504–6.
   Google Scholar
• Yan F-f, Liu Y-F, Liu Y, Zhao Y-X. (2009). Sulfotanshinone sodium injection could decrease fibrinogen level and improve clinical outcomes in patients with unstable angina pectoris. Int J Cardiol 135:254–5.
   PubMed Web of Science ®Google Scholar
• Yu C, Ye S, Sun H, et al. (2009). PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact 177:58–64.
   PubMed Web of Science ®Google Scholar
• Yu H, Subedi RK, Nepal PR, et al. (2012). Enhancement of solubility and dissolution rate of cryptotanshinone, tanshinone I and tanshinone IIA extracted from Salvia miltiorrhiza. Arch Pharm Res 35:1457–64.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Zhuang SW, Lu C, et al. (2019). Clinical effect of sodium tanshinone IIA sulfonate combined with simvastatin on coronary heart disease with angina pectoris and effects on the hemorheology, serum TNF-α, CRP, ET-1 and NO levels. Prog Mod Biomed 19:270–4.
   Google Scholar
• Zhang Z, Ge B, Zhou L, et al. (2014). Induction of liver cytochrome P450s by Danshen–Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. J Ethnopharmacol 154:672–86.
   PubMed Web of Science ®Google Scholar
• Zhuang W, Sun N, Wang J, et al. (2019). Role and experience of clinical pharmacist in the combination of warfarin and traditional Chinese medicine. China Pharmacist 22:1072–6.
   Google Scholar
• Zuo Z, Wo SK, Lo CM, et al. (2010). Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 52:305–10.
   PubMed Web of Science ®Google Scholar